Technology Sector Intelligence: AI Infrastructure Enters the Scarcity Phase — April 2026
The technology sector’s strategic center of gravity has shifted from software scalability to physical infrastructure scarcity. In Q1 2026, energy availability emerged as the primary binding constraint on AI infrastructure expansion, signaling that boards...
From Zero to 100 Percent: The Section 232 Pharmaceutical Tariff and the Board Decision Window That Is Closing
On April 2, 2026, the White House imposed a 100 percent tariff on imports of patented pharmaceuticals and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. For the 17 named companies listed in Annex III of the proclamation,...
The 100% Pharmaceutical Tariff: Three Paths, One Board Decision, 100 Days
President Trump’s April 2, 2026, Proclamation under Section 232 of the Trade Expansion Act of 1962 establishes a 100 percent ad valorem tariff on patented pharmaceutical products and their associated active pharmaceutical ingredients (APIs) imported into the...
The 105-Day Pharmaceutical Compliance Window: Board Action Required Before July 31
The pharmaceutical sector entered a new regulatory epoch on April 2, 2026. President Trump’s Section 232 proclamation imposed tariffs of up to 100% on patented pharmaceutical imports and active pharmaceutical ingredients (APIs), citing national security grounds under...